Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

Affiliations

• ¹ Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
• ² Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
• ³ Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
• ⁴ Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ⁵ Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, San Gerardo Hospital, University of Milan Bicocca, Monza, Italy.
• ⁶ MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK.
• ⁷ Academic Laboratory of Medical Genetics, Lv 6 Addenbrooke's Treatment Centre, Addenbrooke's Hospital, Box 238, Cambridge, CB2 0QQ, UK.
• ⁸ Unit of Gynecological Oncology Research, IEO, European Institute of Oncology IRCCS, Milan, Italy.
• ⁹ Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. giovanna.damia@marionegri.it.